Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 9/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1454680 | 0.94 | KDR (0.45) | BRAFKDR | |
| SCHEMBL1454749 | 0.91 | KDR (0.40) | EGFRBRAFAURKBKDR | |
| SCHEMBL1455910 | 0.90 | BRAF (0.50) | POLBBRAFKDRABL1BCR | |
| SCHEMBL1454493 | 0.89 | KDR (0.41) | EGFRBRAFKDR | |
| SCHEMBL1454675 | 0.89 | KDR (0.39) | BRAFKDR | |
| SCHEMBL1455661 | 0.89 | RPS6KB1 (0.41) | EGFRBRAFAURKBKDR | |
| SCHEMBL1454291 | 0.88 | KDR (0.45) | EGFRBRAFKDRMAPK14 | |
| SCHEMBL1455304 | 0.88 | KDR (0.42) | EGFRBRAFAURKBKDRABL1 | |
| SCHEMBL1455908 | 0.88 | MAPK14 (0.44) | EGFRAURKBMAPK14 | |
| SCHEMBL1455506 | 0.88 | BRAF (0.40) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1979348-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076034-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | POLB 442/4885EGFR 2701/4885BRAF 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.